Abstract:Previous studies have reported the stepwise nature of human immunodeficiency virus type 1 (HIV-1) entry and the pivotal role of coreceptor CCR5 and the gp41 N-terminal heptad repeat (NHR) region in this event. With this in mind, we herein report a dual-targeted drug compound featuring bifunctional entry inhibitors, consisting of a piperidine-4-carboxamide-based CCR5 antagonist, TAK-220, and a gp41 NHR-targeting fusion-inhibitory peptide, C34. The resultant chimeras were constructed by linking both pharmacophores with a polyethylene glycol spacer. One chimera, CP12TAK, exhibited exceptionally potent antiviral activity, about 40- and 306-fold over that of its parent inhibitors, C34 and TAK-220, respectively. In addition to R5-tropic viruses, CP12TAK also strongly inhibited infection of X4-tropic HIV-1 strains. These data are promising for the further development of CP12TAK as a new anti-HIV-1 drug. Results show that this strategy could be extended to the design of therapies against infection of other enveloped viruses.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00781?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00781</a>.HPLC method used for the purification of peptide compounds; HPLC method used for the analysis of peptide compounds; potential cytotoxicity of CP12TAK on CEMx174 5.25M7 and MT-2 cells; MALDI-TOF-MS and Analytical HPLC of designed peptides; <sup>1</sup>H and <sup>13</sup>C NMR spectra of small-molecule compounds; and ESI-TOF-MS spectra of small-molecule compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00781/suppl_file/jm1c00781_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00781/suppl_file/jm1c00781_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

N-Phenyl-N'-(2,2,6,6-Tetramethyl-Piperidin-4-Yl)-Oxalamides As A New Class Of Hiv-1 Entry Inhibitors That Prevent Gp120 Binding To Cd4

Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4

Design, Synthesis, and Structure−Activity Relationship of a Novel Series of 2-Aryl 5-(4-Oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 Entry Inhibitors<sup>⊥</sup>

In Silico Identification of Novel Aromatic Compounds As Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors

N-Substituted Pyrrole Derivatives As Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the Gp41 Six-Helix Bundle Formation and Block Virus Fusion

N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein

N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.

Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors

Design, Synthesis, and Biological Activity of Novel 5-((Arylfuran/1h-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones As HIV-1 Fusion Inhibitors Targeting Gp41.

In Silico Identification of High-Affinity Ligands of the Hiv-1 Gp120 Protein, Potential Peptidomimetics of Neutralizing Antibody N6

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

Soluble-type small-molecule CD4 mimics as HIV entry inhibitors

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

Design, Synthesis, and Biological Evaluation of N-Carboxyphenylpyrrole Derivatives As Potent HIV Fusion Inhibitors Targeting Gp41

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Synthesis And Biological Evaluation Of Novel 5-Alkyl-2-Arylthio-6-((3,4-Dihydroquinolin-1(2h)-Yl)Methyl)Pyrimidin-4(3 H)-Ones As Potent Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors

Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane